{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=34&q=fallopian+tube",
    "query": {
      "q": "fallopian tube",
      "condition": "Ovarian Cancer",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 739,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=35&q=fallopian+tube&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=33&q=fallopian+tube&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T18:57:34.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04092270",
      "title": "A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Endometrial High Grade Endometrioid Adenocarcinoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube High Grade Serous Adenocarcinoma",
        "Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fallopian Tube Undifferentiated Carcinoma",
        "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma",
        "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma",
        "Ovarian High Grade Serous Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Undifferentiated Carcinoma",
        "Platinum-Sensitive Ovarian Carcinoma",
        "Primary Peritoneal Carcinosarcoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Primary Peritoneal Transitional Cell Carcinoma",
        "Primary Peritoneal Undifferentiated Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Ovarian Endometrioid Adenocarcinoma",
        "Recurrent Ovarian Low Grade Serous Adenocarcinoma",
        "Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor",
        "Recurrent Ovarian Mucinous Adenocarcinoma",
        "Recurrent Ovarian Transitional Cell Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Peposertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 55,
      "start_date": "2020-05-07",
      "completion_date": "2027-06-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04092270"
    },
    {
      "nct_id": "NCT01381861",
      "title": "Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Fallopian Tube Carcinoma",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carotuximab (TRC105)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tracon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2011-07",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01381861"
    },
    {
      "nct_id": "NCT01001910",
      "title": "Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pemetrexed Disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2008-07",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 3,
      "location_summary": "New York, New York • The Bronx, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01001910"
    },
    {
      "nct_id": "NCT03907527",
      "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Refractory Fallopian Tube Carcinoma",
        "Refractory Ovarian Carcinoma",
        "Refractory Primary Peritoneal Carcinoma",
        "Stage III Fallopian Tube Cancer AJCC V8",
        "Stage III Ovarian Cancer AJCC V8",
        "Stage III Primary Peritoneal Cancer AJCC V8",
        "Stage IIIA Fallopian Tube Cancer AJCC V8",
        "Stage IIIA Ovarian Cancer AJCC V8",
        "Stage IIIA Primary Peritoneal Cancer AJCC V8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC V8",
        "Stage IIIA1 Ovarian Cancer AJCC V8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC V8",
        "Stage IIIA2 Ovarian Cancer AJCC V8",
        "Stage IIIB Fallopian Tube Cancer AJCC V8",
        "Stage IIIB Ovarian Cancer AJCC V8",
        "Stage IIIB Primary Peritoneal Cancer AJCC V8",
        "Stage IIIC Fallopian Tube Cancer AJCC V8",
        "Stage IIIC Ovarian Cancer AJCC V8",
        "Stage IIIC Primary Peritoneal Cancer AJCC V8",
        "Stage IV Fallopian Tube Cancer AJCC V8",
        "Stage IV Ovarian Cancer AJCC V8",
        "Stage IV Primary Peritoneal Cancer AJCC V8",
        "Stage IVA Fallopian Tube Cancer AJCC V8",
        "Stage IVA Ovarian Cancer AJCC V8",
        "Stage IVA Primary Peritoneal Cancer AJCC V8",
        "Stage IVB Fallopian Tube Cancer AJCC V8",
        "Stage IVB Ovarian Cancer AJCC V8",
        "Stage IVB Primary Peritoneal Cancer AJCC V8"
      ],
      "interventions": [
        {
          "name": "PRGN-3005 UltraCAR-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 71,
      "start_date": "2019-04-30",
      "completion_date": "2028-11-15",
      "has_results": false,
      "last_update_posted_date": "2024-11-08",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Seattle, Washington",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907527"
    },
    {
      "nct_id": "NCT00003385",
      "title": "Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 48,
      "start_date": "1999-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 7,
      "location_summary": "Honolulu, Hawaii • Iowa City, Iowa • Bethesda, Maryland + 3 more",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003385"
    },
    {
      "nct_id": "NCT05128825",
      "title": "A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "azenosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 310,
      "start_date": "2022-02-17",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 43,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05128825"
    },
    {
      "nct_id": "NCT01223235",
      "title": "Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fallopian Tubes Cancer",
        "Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2010-10",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2018-06-12",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01223235"
    },
    {
      "nct_id": "NCT02346747",
      "title": "A Trial of Vigil for Participants With Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2015-02",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Irvine, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02346747"
    },
    {
      "nct_id": "NCT00866697",
      "title": "Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 940,
      "start_date": "2009-05-26",
      "completion_date": "2017-08-24",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 35,
      "location_summary": "Anaheim, California • Baldwin Park, California • Bellflower, California + 27 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fontana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00866697"
    },
    {
      "nct_id": "NCT01296035",
      "title": "Panitumumab and Gemcitabine in Relapsed Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Panitumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Women and Infants Hospital of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2011-02",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-08-25",
      "last_synced_at": "2026-10-15T18:57:34.813Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01296035"
    }
  ]
}